{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.65","upperLimit":"0.84","value":"0.76"},{"groupId":"OG001","lowerLimit":"0.19","upperLimit":"0.63","value":"0.42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS.","dispersionType":"90% Confidence Interval","groups":[{"description":"Eligible and treated patients who were PET negative after 3 cycles of R-CHOP received 2 more cycles of R-CHOP (6 cycles in total).","id":"OG000","title":"Group I (PET Negative)"},{"description":"Eligible and treated patients who were PET positive after 3 cycles of R-CHOP received 4 cycles of R-ICE.","id":"OG001","title":"Group II (PET Positive)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.","title":"2-year Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"probability"}